Analyst Ratings For BioMarin Pharmaceutical (NASDAQ:BMRN)
Today, Jefferies Group LLC reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ:BMRN) with a price target of $116.00.
There are 7 hold ratings, 15 buy ratings on the stock.
The current consensus rating on BioMarin Pharmaceutical (NASDAQ:BMRN) is Buy (Score: 2.68) with a consensus target price of $110.80 per share, a potential 17.55% upside.
Some recent analyst ratings include
- 9/26/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 9/21/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 9/15/2017-BMO Capital Markets Reiterated Rating of Buy.
- 9/14/2017-Royal Bank Of Canada initiated coverage with a Sector Perform rating.
- 8/31/2017-Citigroup Inc. initiated coverage with a Buy rating.
- 8/16/2017-Evercore ISI initiated coverage with a Outperform rating.
- 8/9/2017-Deutsche Bank AG Reiterated Rating of Buy.
Recent Insider Trading Activity For BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) has insider ownership of 2.50% and institutional ownership of 97.46%.
- On 9/15/2017 Henry J Fuchs, Insider, sold 15,000 with an average share price of $90.50 per share and the total transaction amounting to $1,357,500.00. View SEC Filing
- On 9/15/2017 V Bryan Lawlis, Director, sold 3,750 with an average share price of $91.26 per share and the total transaction amounting to $342,225.00. View SEC Filing
- On 6/23/2017 George Eric Davis, EVP, sold 9,844 with an average share price of $96.60 per share and the total transaction amounting to $950,930.40. View SEC Filing
- On 6/22/2017 Brian Mueller, SVP, sold 2,671 with an average share price of $100.00 per share and the total transaction amounting to $267,100.00. View SEC Filing
- On 6/19/2017 Henry J Fuchs, Insider, sold 15,000 with an average share price of $90.00 per share and the total transaction amounting to $1,350,000.00. View SEC Filing
- On 6/16/2017 V Bryan Lawlis, Director, sold 3,750 with an average share price of $90.00 per share and the total transaction amounting to $337,500.00. View SEC Filing
- On 6/7/2017 Jeffrey Robert Ajer, EVP, sold 1,004 with an average share price of $89.61 per share and the total transaction amounting to $89,968.44. View SEC Filing
Recent Trading Activity for BioMarin Pharmaceutical (NASDAQ:BMRN)
Shares of BioMarin Pharmaceutical closed the previous trading session at with shares trading hands.